Jazz Pharmaceuticals plc and Redx Pharma plc have signed a definitive agreement under which Jazz will acquire Redx’s KRAS inhibitor program.

Invitae Corp. has entered into a partnership with Bridgebio Pharma Inc. to advance genetics-based drug discovery for rare diseases. The goal of the collaboration is to generate new insights focused on genetic modifiers and the discovery of novel therapeutic targets for rare diseases and other unmet medical needs.

Ractigen Therapeutics Co. Ltd. has entered into a formal collaboration with University Medical Center Utrecht, affiliated with Utrecht University, to advance the development of small activating RNA (saRNA)-based treatments for a spectrum of intractable neurodevelopmental disorders.

Synthekine Inc. has established a worldwide collaboration with Sanofi SA to develop and commercialize IL-10 receptor agonists for the treatment of inflammatory diseases.